Brief: SynAct Pharma: Approval Of Amended Study Protocol For Phase 2a Study In iMN

SynAct Pharma AB

14/09/2022 06:14

Sept 14 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * APPROVAL OF AMENDED STUDY PROTOCOL FOR THE PHASE 2A STUDY
IN IMN

Source text for Eikon:  ID:nMFNbzF0x5 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))